Hope Rising for Chemo-Induced Neuropathy Treatment

In the world of cancer treatment, the market for chemotherapy-induced peripheral neuropathy (CIPN) is set to grow significantly from 2026 to 2036, with a future full of promising therapies. The high demand is fueled by the rising cases of CIPN due to increased use of neurotoxic chemotherapy drugs. Companies like Averitas Pharma and Dogwood Therapeutics are leading the charge with new drugs in the pipeline, aiming to shift treatment focus from just managing symptoms to addressing the root causes of CIPN. What does it mean for you? If you or a loved one is undergoing chemotherapy, there's hope on the horizon for more effective treatments. With new therapies in development, there's potential for improved quality of life and better management of chemo side effects.